NEW YORK--(BUSINESS WIRE)--Rodman & Renshaw, LLC, a wholly owned subsidiary of Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM) announced that it has acted as a co-manager to its client ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA - News), who today announced the pricing of an underwritten public offering of 21,500,000 shares of its common stock, at a price to the public of $10.42 per share. The offering is expected to close on or about December 20, 2011, subject to customary closing conditions. In addition, ARIAD has granted the underwriters a 30-day option to purchase up to 3,225,000 additional shares of common stock to cover over-allotments, if any.
